Heparin therapy in venous thromboembolism

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Pulmonary embolism (PE) and deep venous thrombosis (DVT) are serious conditions requiring anticoagulation.
• Heparin is a common anticoagulant, administered via intermittent or continuous intravenous methods.
• The optimal administration method for heparin in VTE treatment remains a subject of investigation.

Purpose of the Study:

• To compare the efficacy and safety of intermittent versus continuous intravenous heparin therapy in patients with PE or DVT.
• To evaluate the impact of bleeding risk factors on the outcomes of different heparin administration methods.

Main Methods:

• Randomized controlled trial comparing intermittent and continuous intravenous heparin.
• Patients with PE or DVT were assigned to one of the two treatment groups.
• Bleeding complications and recurrent thromboembolic events were monitored.

Main Results:

• Major bleeding was significantly higher with intermittent heparin in patients with increased bleeding risk.
• Recurrent thromboembolism occurred more frequently with continuous heparin therapy.
• Higher daily heparin doses were administered with intermittent injections compared to continuous infusion when controlled by coagulation tests.

Conclusions:

• In patients without bleeding risk factors, higher-dose intermittent heparin is preferred due to fewer recurrences and similar bleeding rates.
• In high-risk bleeding patients, continuous heparin at conventional doses reduces bleeding but increases recurrence risk.
• Dose adjustments and administration methods significantly influence heparin's safety and efficacy profile in VTE management.